Zimbabwe is again at a crossroads in health policy. The proposed amendments to the Medical Aid Societies Regulations, 2000 (S.I. 330/2000) are being framed as a “clean‑up” — a move to address perceived conflict‑of‑interest concerns by prohibiting medical aid societies (and related entities) from owning, managing, operating, or holding interests in healthcare service‑provider assets.
But let us be candid: this is not a tidy technical adjustment. It is a blunt, structural intervention — one that seeks to ban a model that has evolved in Zimbabwe for practical reasons, and then compel divestiture of lawfully held healthcare assets on a tight timeline.
If implemented, it will not punish “institutions”. It will punish patients — especially low‑income contributors — by raising costs, shrinking access, and weakening the very health‑financing pools that help families and employers survive in a volatile economic environment.
A ban on service provision is a ban on member protection
The proposed amendment’s core thrust is clear: it aims to outlaw service provision by medical aid societies and force disinvestment through a divestiture plan, followed by disinvestment within 24 to 36 months.
That is not “governance”. That is forced separation and forced disposal — regardless of whether the facilities are keeping costs down, filling gaps left by the market, or ensuring continuity of care.
In Zimbabwe, medical aid service provision did not emerge as a boardroom fad. It emerged because the healthcare system repeatedly confronted conditions where the alternative was simply no care, or care priced out of reach.
Take one real and familiar trajectory in the sector: in the late 1980s into the 1990s, the risk of skilled professionals leaving the country threatened the survival of critical services such as laboratory capacity. Where there was no successor ownership and no private actor stepping in, societies faced an unavoidable question: do we watch a vital service disappear and leave members stranded, or do we intervene to keep diagnostic access alive?
Later, in the early 2000s — particularly around 2004 during hyperinflation — pricing instability was so severe that many providers refused to accept medical aid cards and demanded cash upfront, pushing members into a dangerous “pay‑now, claim‑later” reality. The result was predictable: members became vulnerable, and medical aid cover risked becoming theoretical. To preserve access, societies had to innovate and stabilise service routes — particularly through primary care and pharmacy platforms.
The point is simple: when the system fails, members still get sick. Their needs do not pause until policy becomes tidy.
This proposal will raise prices — and we already know why
Zimbabwe’s private healthcare market has long struggled with tariff discipline. Even today, providers are not governed by a common tariff framework, and price escalation is routinely passed directly to households through shortfalls and co‑payments.
In that environment, integrated service provision has functioned as a stabiliser — a practical “price and access backstop”. It protects members when external tariffs, shortfalls and co‑payments make care unaffordable, and it supports continuity of care for chronic patients and lower‑income contributors.
Remove that stabiliser, and you do not create a “more ethical market”. You create a more expensive one — because you weaken purchaser leverage, you force members back into uncontrolled pricing, and you strip away the one mechanism that has historically counterbalanced tariff opacity and price shocks.
The equity issue: low‑income members will be hit first and hardest
We must say this plainly: medical aid in Zimbabwe is not only for high‑income earners. Many products intentionally target lower‑income contributors — the very people who would otherwise have no credible access pathway to private care.
But in today’s pricing environment, low‑income packages face a structural risk: external consultation and treatment costs can quickly exceed what those members contribute, making them vulnerable to exclusion or “pricing out” by service providers.
And while public facilities should ideally provide the safety net, the reality is that capacity constraints and deterioration in parts of the public system make that fallback unreliable for many communities.
That is why parallel service provision units matter: they allow societies to align care access with package realities, protect vulnerable members from discrimination-by-pricing, and keep healthcare within reach of the very citizens policy claims to protect.
If the proposed amendment proceeds without solving the underlying pricing and capacity problems, the predictable outcome is greater inequality: better‑off members will still find alternatives; lower‑income members will be squeezed out.
If the concern is conflict of interest, the solution is targeted regulation — not demolition
Let us also deal honestly with the stated justification. Yes, any model can be abused — including vertical integration. But “potential conflict of interest” is not a justification to dismantle lawful, member‑financed healthcare infrastructure.
Conflicts of interest are a conduct and governance issue. They are addressed through ring‑fencing, transparency, related‑party controls, open-network safeguards, auditability, and clear consumer‑protection rules — not through blanket prohibition.
This is not a radical stance. It is consistent with modern regulatory practice, which typically regulates conduct and market power, rather than banning ownership in the absence of evidence of harm.
And crucially: Zimbabwe already has a competition framework designed to deal with market dominance, restrictive practices, and anti‑competitive conduct. The appropriate response to competition concerns is competition oversight — not a one‑size‑fits‑all ban that applies regardless of market share, geography, or consumer harm.
The legal and constitutional problem: this looks like delegated overreach
There is a further issue policymakers should not underestimate: legality.
A central concern already articulated in formal legal engagement is that the proposed amendments may be ultra vires the enabling statute (the Medical Services Act [Chapter 15:13]) because the parent Act does not, on this view, contain powers to regulate ownership structures, prohibit vertical integration, or authorise compulsory divestiture of assets.
In other words, this is not just a policy dispute — it is potentially a rule‑of‑law problem. If government wishes to introduce a prohibition of this magnitude, the proper route is primary legislation (an Act of Parliament), supported by public hearings and a transparent impact assessment — not a sweeping structural rewrite by subordinate legislation.
Members must be heard — because these are member investments
One of the most troubling features of this process is the imbalance of voice.
At consultations, provider associations have been strongly represented, and their preferences are clear. But the people with the greatest direct stake — the members whose pooled contributions created these assets — risk being sidelined.
Yet societies are stewards of member funds. These investments exist for members’ welfare. It is therefore not merely advisable, but ethically necessary, that reforms of this magnitude include direct member consultation — not as an afterthought, but as a central pillar of legitimacy.
This is why the call for structured public hearings is not “politics”. It is basic fairness.
What Zimbabwe should do instead: fix the real problems
If the real goal is affordability, transparency, and patient protection, then Zimbabwe should pursue reforms that actually target the drivers of dysfunction:
- Targeted regulation, not prohibition — address conduct and governance risks without destroying capacity.
- Transparency and related‑party controls — enforce disclosure, audited transfer pricing, and ring‑fenced governance where integration exists.
- Open-network safeguards — protect patient choice and prevent anti‑competitive steering through clear rules.
- Tariff monitoring and enforcement — the pricing problem cannot be solved by banning funders; it must be solved by confronting tariff opacity and uncontrolled escalation.
- Competition oversight where market power exists — use existing competition tools to address dominance and restrictive practices rather than imposing a blanket structural ban.
That is how you protect consumers. That is how you advance Universal Health Coverage. That is how you strengthen — rather than fracture — a fragile system.
Bottom line: don’t sacrifice patients on the altar of a simplistic theory
Zimbabwe cannot regulate as if it has the healthcare depth and pricing discipline of far more resourced systems. We must regulate for the Zimbabwe we have — one where capacity is constrained, affordability is fragile, and medical aid coverage is limited.
In that environment, banning service provision and forcing divestiture is not reform. It is regression.
If government’s objective is truly the public interest, it should pause this prohibition, insist on evidence, conduct an impact assessment, hear members directly, and pursue targeted safeguards that address real risks without dismantling member‑financed access routes.
Because the people who will pay the price are not “institutions”. They are patients.